Mycofenolate mofetil versus cyclophosphamide for steroid-resistant nephrotic syndrome in children

Revista Romana de PEDIATRIE | Volumul LX, Nr. 2, An 2011

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

Florentina Cucer, Ingrith Miron, Mihaela Munteanu, Codruţa Iliescu Haliţchi, R. Muller, R. Russu, Anca Ivanov, Doina Mihaila and O. Brumariu

ABSTRACT

The management of patients with steroid-resistant nephrotic syndrome is difficult. We report our experience on treatment with Mycophenolate mofetil versus Cyclophosphamide, in a retrospective analysis of 54 cases of idiopathic steroid-resistant nephrotic syndrome with different histological aspects. The complete and sustained remission rate was 50% for Mycophenolate, which confirm the efficacy of treatment, higher than with Cyclophosphamide (39.53%).

Key words: nephrotic syndrome, mycophenolate mofetil, cyclophosphamide, steroid-resistancy

Full text | PDF